IMPACT BIOMEDICAL INC. (IBO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 20K 40K 60K Q1 '22: 0 Q2 '22: 50K Q3 '22: 0 Q4 '22: 0 Q2 '25: 7K Q3 '25: 18K Q4 '25: 7K Q1 '26: 7K Q2 '26: 3K Q1 '22 Q3 '22 Q2 '25 Q4 '25 Q2 '26

Gross Profit Quarterly

0 2.5K 5K 7.5K Q2 '25: 6K Q2 '26: 2K Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-27M -18M -9M 0 9M 18M 27M Q1 '22: -733K Q2 '22: -750K Q3 '22: -889K Q4 '22: -1M Q1 '23: -803K Q2 '23: -1M Q3 '23: -1.1M Q4 '23: -1.1M Q1 '24: -771K Q2 '24: -626K Q3 '24: -1.1M Q4 '24: -26.2M Q1 '25: -1M Q2 '25: -1.2M Q3 '25: -948K Q4 '25: -1.2M Q1 '26: -2.3M Q2 '26: -702K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q1 '22: -854K Q2 '22: -799K Q3 '22: -2.2M Q4 '22: -3.4M Q1 '23: -849K Q2 '23: -1.1M Q3 '23: -1.2M Q4 '23: -1.2M Q1 '24: -962K Q2 '24: -889K Q3 '24: 4.2M Q4 '24: -27.1M Q1 '25: -1.3M Q2 '25: -14.3M Q3 '25: -1.5M Q4 '25: 5.2M Q1 '26: -2.3M Q2 '26: -699K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 150K 300K 450K Q2 '25: 1K Q3 '25: 1K Q4 '25: 422K Q2 '26: 1K Q2 '25 Q3 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q3 '22: -802K Q4 '22: -363K Q1 '23: -1M Q2 '23: -733K Q3 '23: -671K Q4 '23: -433K Q1 '24: -482K Q2 '24: -385K Q3 '24: -1M Q4 '24: -986K Q1 '25: -682K Q2 '25: -694K Q3 '25: -613K Q4 '25: 99K Q1 '26: -464K Q2 '26: 470K Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 1.5B 3B 4.5B Q2 '22: 3.9B Q3 '22: 70.5M Q1 '23: 70.5M Q2 '23: 70.5M Q3 '23: 70.5M Q1 '24: 10M Q2 '24: 10M Q3 '24: 11.5M Q1 '25: 12.1M Q2 '25: 12.2M Q3 '25: 12.2M Q1 '26: 107.8M Q2 '26: 107.8M Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '22: -0.10 Q1 '23: -0.08 Q2 '23: -0.10 Q3 '23: -0.09 Q4 '23: -0.08 Q1 '24: -0.17 Q2 '24: -0.24 Q3 '25: -3.74 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.